Cutting the cost of South African antiretroviral therapy using newer, safer drugs.
S Afr Med J
; 107(1): 28-30, 2016 Dec 21.
Article
en En
| MEDLINE
| ID: mdl-28112085
Antiretrovirals are a significant cost driver for HIV programmes. Current first-line regimens have performed well in real-life programmes, but have a low barrier to virological resistance and still carry toxicity that limits adherence. New drug developments may mean that we have access to safer, more robust and cheaper regimens, but only if the appropriate clinical trials are conducted. We briefly discuss these trials, and demonstrate the large cost savings to the South African HIV programme if these are successful.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
Costos de los Medicamentos
/
Ahorro de Costo
/
Fármacos Anti-VIH
/
Terapia Antirretroviral Altamente Activa
Tipo de estudio:
Health_economic_evaluation
Límite:
Humans
País/Región como asunto:
Africa
Idioma:
En
Revista:
S Afr Med J
Año:
2016
Tipo del documento:
Article
País de afiliación:
Sudáfrica
Pais de publicación:
Sudáfrica